Last reviewed 2026-04-23 · How we verify

Pro-Thrombin Concentrate Complex

Prothrombin Complex Concentrate (PCC) replaces deficient vitamin K-dependent clotting factors (II, VII, IX, X) to restore coagulation cascade function.

Prothrombin Complex Concentrate (PCC) replaces deficient vitamin K-dependent clotting factors (II, VII, IX, X) to restore coagulation cascade function. Used for Reversal of warfarin-induced anticoagulation in patients with serious or life-threatening bleeding, Urgent reversal of vitamin K antagonist anticoagulation.

At a glance

Mechanism of action

PCC is a pooled plasma-derived product containing the vitamin K-dependent factors II, VII, IX, and X (4-factor PCC) or factors II, VII, IX, X plus protein C and S (activated PCC). It rapidly reverses anticoagulation caused by warfarin or other vitamin K antagonists by replenishing depleted clotting factors, thereby restoring the extrinsic and common coagulation pathways.

Approved indications

• Reversal of warfarin-induced anticoagulation in patients with serious or life-threatening bleeding
• Urgent reversal of vitamin K antagonist anticoagulation

Common side effects

• Thromboembolism (venous thromboembolism, myocardial infarction, stroke)
• Disseminated intravascular coagulation (DIC)
• Allergic/hypersensitivity reactions
• Fever
• Headache

Key clinical trials

• Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Pro-Thrombin Concentrate Complex CI brief — competitive landscape report
• Pro-Thrombin Concentrate Complex updates RSS · CI watch RSS
• University Hospital, Grenoble portfolio CI